<DOC>
	<DOCNO>NCT02603835</DOCNO>
	<brief_summary>The primary objective study collect confirmatory data support safety effectiveness SSO2 Therapy treatment anterior acute myocardial infarction ( AMI ) patient undergone successful percutaneous coronary intervention ( PCI ) stenting within six hour experience AMI symptom .</brief_summary>
	<brief_title>Evaluation Intracoronary Hyperoxemic Oxygen Therapy Anterior Acute Myocardial Infarction Patients ( IC-HOT )</brief_title>
	<detailed_description>A Multi-Center , Consecutively Enrolled Single-Arm Study confirm safety effectiveness delivery supersaturated oxygen ( SSO2 ) Therapy 60 minute selectively leave main coronary artery ( LMCA ) commercially available qualified SSO2 delivery catheter use TherOx® DownStream® System Cartridge treatment qualify patient present anterior acute myocardial infarction reperfusion PCI successful within six hour symptom onset .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>GENERAL INCLUSION CRITERIA : Candidates study must meet ALL follow criterion : PrePCI : 1 . The subject must ≥18 ≤80 year age . 2 . AMI must anterior ( STsegment elevation &gt; 1 mm two contiguous lead V1 V4 new leave bundle branch block ) . 3 . Subject experience clinical symptom consistent anterior AMI ≤6 hour duration time symptom onset admission emergency room . 4 . The subject legally authorize representative inform nature study , agree provision provide sign write informed consent , approve appropriate Institutional Review Board ( IRB ) . 5 . Subject his/her physician agree require followup procedure visit . ANGIOGRAPHIC INCLUSION CRITERIA : These evaluate subject provide sign informed consent prior enrollment : 6 . Based coronary anatomy , PCI indicate revascularization culprit lesion ( ) use commercially available coronary stent ( bare metal drugeluting , operator discretion ) LAD . 7 . The primary stented infarctrelated lesion ( ) must proximal and/or midLAD coronary artery ( lesion LAD target vessel , include diagonal branch , may treat clinically indicate ) . 8 . Baseline ( prePCI ) TIMI flow grade 0 , 1 , 2 , 3 flow LAD . 9 . Successful angioplasty document &lt; 50 % diameter residual angiographic stenosis within treat culprit lesion TIMI 2 3 flow major complication perforation shock . 10 . Expected ability place SSO2 delivery catheter coronary ostium leave main coronary system deliver SSO2 Therapy stable , coaxial alignment . GENERAL EXCLUSION CRITERIA : PrePCI : 1 . Prior CABG surgery . 2 . Prior myocardial infarction , know prior systolic dysfunction ( know ejection fraction &lt; 40 % prior measure regional wall motion abnormality ; criterion include leave ventricular dysfunction induce acute MI ) . 3 . Thrombolytic therapy administer STEMI . 4 . An elective surgical procedure plan would necessitate interruption antiplatelet agent first 30 day postenrollment . 5 . Subjects previously underwent coronary stent implantation coronary angiography demonstrate stent thrombosis cause anterior AMI . 6 . Subjects previously undergo angioplasty stenting procedure leave anterior descend coronary artery . 7 . Subjects ventricular pseudoaneurysm , VSD , severe mitral valve regurgitation ( without papillary muscle rupture ) . 8 . Any contraindication MRI imaging . This include follow exclusion : Cardiac pacemaker implantable defibrillator ; NonMRI compatible aneurysm clip ; Neural Stimulator ( i.e. , TENS unit ) ; Any implant magnetically activate device ( insulin pump ) ; Any type nonMRI compatible ear implant ; Metal shave orbit ; Any metallic foreign body , shrapnel , bullet location physician feel would present risk subject ; Any history indicate contraindication MRI , include claustrophobia allergy gadolinium ; Inability follow breath hold instruction maintain breath hold &gt; 15 second ; Known hypersensitivity contraindication gadolinium contrast . 9 . Known impaired renal function ( creatinine clearance &lt; 30 ml/min/1.73 m2 10 . Known platelet count &lt; 100,000 cells/mm MDRD formula ) dialysis . 3 &gt; 700,000 cells/mm3 11 . Subject active bleeding history bleed diathesis coagulopathy ( include heparin induce thrombocytopenia ) , refusal receive blood transfusion necessary . know Hgb &lt; 10 g/dL . 12 . History intracerebral mass , aneurysm , arteriovenous malformation , hemorrhagic stroke . 13 . Stroke transient ischemic attack within past six ( 6 ) month , permanent neurological defect . 14 . Gastrointestinal genitourinary bleeding within last two ( 2 ) month , major surgery ( include CABG ) within six week enrollment . 15 . Subject receive organ transplant wait list organ transplant . 16 . Subject medical illness ( e.g. , cancer , dementia ) know history substance abuse ( alcohol , cocaine , heroin , etc . ) may cause noncompliance protocol , confound data interpretation , associate limited life expectancy le one year . 17 . Subject know hypersensitivity contraindication unfractionated heparin , abciximab , aspirin , bivalirudin , cangrelor , clopidogrel , ticlopidine , prasugrel , ticagrelor adequately premeditate . 18 . Current use warfarin , dabigatran , factor Xa inhibitor , know intent administer agent primary PCI . 19 . Subjects present develop cath lab prior completion primary PCI procedure follow condition : cardiogenic shock ( SBP &lt; 80 mmHg &gt; 30 minute ) , require IV pressor emergent placement intraaortic balloon pump ( IABP ) , Impella , hemodynamic support hypotension treatment , cardiopulmonary resuscitation &gt; 10 minute , ventricular fibrillation tachycardia require cardioversion defibrillation . 20 . Severe know cardiac valvular stenosis insufficiency , pericardial disease , nonischemic cardiomyopathy . 21 . Any significant medical social condition investigator 's opinion may interfere subject 's participation study ability comply followup procedure , include MRI ( e.g . alcoholism , dementia , live far research center , etc. ) . 22 . Current participation investigational device drug trial finish primary endpoint followup period . 23 . Previous enrollment study . ANGIOGRAPHIC EXCLUSION CRITERIA : These evaluate subject provide sign Informed Consent prior enrollment : 24 . Anticipated inability achieve stable coaxial position leave main coronary artery SSO2 delivery catheter . 25 . Treatment index procedure lesion either leave main , LCX ( include ramus ) , and/or RCA . 26 . Postindex procedure plan intervention within 30 day ( i.e. , PCI nontarget lesion vessel , CABG ) . Note : Planned revascularization ( PCI bypass ) nontarget lesion &gt; 30 day follow index procedure allow . 27 . Anterior MI due thrombosis within adjacent previously implant stent . 28 . Left ventriculography demonstrate severe mitral regurgitation , ventricular septal defect , pseudoaneurysm . 29 . Any leave main coronary artery stenosis &gt; 20 % . 30 . Any untreated LAD diagonal branch lesion present diameter stenosis &gt; 50 % vessel reference vessel diameter &gt; 2.0 mm ( visually estimate ) , PCI require MRI study . 31 . Presence nonstented coronary dissection NHLBI grade &gt; B upon completion PCI procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>SSO2 Therapy</keyword>
	<keyword>Acute myocardial infarction</keyword>
	<keyword>Anterior myocardial infarction</keyword>
	<keyword>SuperSaturated oxygen delivery</keyword>
	<keyword>Left main coronary artery</keyword>
	<keyword>Myocardial infarction</keyword>
	<keyword>Heart attack</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Cardiac catheterization laboratory</keyword>
	<keyword>PCI</keyword>
	<keyword>Stent</keyword>
	<keyword>Stenting</keyword>
	<keyword>Stents</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>LMCA</keyword>
	<keyword>Delivery supersaturated oxygen ( SSO2 ) therapy treatment anterior acute myocardial infarction</keyword>
</DOC>